TP53 and cardiac hypertrophy: There are data showing that TP53 inhibits angiogenesis by suppressing HIF-1 resulting in myocardial hypoxia and cardiac dysfunction which may be a novel molecular mechanism underlying transition of cardiac hypertrophy to HF38.